Lotte Biologics has completed the relocation of all employees to the Songdo Bio Campus and is accelerating preparations for commercial production set to begin in 2027.
On August 18, the company announced the official start of the 'Songdo Era' following the completion of the move. This relocation consolidates the previously dispersed headquarters functions and production infrastructure into the Songdo Bio Campus. As a result, collaboration among key departments, including management, production, quality, engineering, and business development, is expected to strengthen, leading to faster decision-making in preparation for commercial production.
Additionally, the company has established a system to quickly reflect customer requirements on the production floor and respond in real-time to manufacturing and quality-related issues.
Previously, Lotte Biologics had announced plans to provide integrated contract development and manufacturing organization (CDMO) services, covering everything from early clinical production to large-scale commercial production, based on its 'Dual Site' strategy. The ability to share real-time updates between the Syracuse Bio Campus in the U.S. and the Songdo production facility is expected to enhance collaboration further.
Lotte Biologics is also accelerating follow-up work to ensure the Songdo production facility is 'GMP Ready.' Currently, the first plant is undergoing a qualification and validation process for equipment and utilities, with plans to establish a Good Manufacturing Practice (GMP) production system that meets global regulatory standards through commissioning and validation of manufacturing and quality systems in the second half of this year. The goal is to commence commercial production in 2027.
The Songdo Bio Campus is expected to become a key hub for large-scale orders, providing stable pharmaceutical production services to global clients through phased expansion of production facilities.
A representative from Lotte Biologics stated, 'The move to Songdo is a significant milestone in consolidating all of the company's capabilities at the Songdo Bio Campus ahead of commercial production. We aim to provide trusted CDMO services to our customers by organically connecting the global production experience accumulated in Syracuse with the state-of-the-art production infrastructure in Songdo.'
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.